TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03407495
Drug: IOP Injection (MPB-1523)
Normalized name: AVOBENZONE 1.25 g in 50 mL / HOMOSALATE 4.5 g in 50 mL / OCTISALATE 2.25 g in 50 mL / OCTOCRYLENE 4.5 g in 50 mL TOPICAL CREAM [IOPE UV DEFENSE SUN PROTECTOR]
DrugBank: Avobenzone (DB09495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one dose, once IV injection at Day 1
Study: NCT00236496
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01228604
Drug: methylphenidate (Ritalin®)
Normalized name: methylphenidate Oral Tablet [Ritalin]
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The scheme provides for initial dose of 0.3 mg / kg / day, with an average dose of 1mg/kg/day. The increases will be made considering the presentation of the drug (10mg), which allows increments of 5mg or 10mg, which will be made in clinical review, as the clinical symptoms, including increasing the dose until there is more room for improvement or there is presence of significant adverse effects, all the patients with indication of treatment will be assessed before the use of medication, 15 days, 30 days, 3 and 6 months after the start,
Study: NCT00102297
Drug: FG-3019
Normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02073838
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02073838
Drug: Vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02073838
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03586323
Drug: superior laryngeal nerve block with lidocaine
Normalized name: Ivy Block
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SLNB was performed with 4 ml of 1.5% lidocaine below the thyroid membrane
Study: NCT04894643
Drug: Nab-PACLitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~It will be administered as intra venous infusion over 30 minutes.
Study: NCT04894643
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~Gemcitabine will also be administered as intra venous infusion over 30 minutes immediately after Nab-PACLitaxel.
Study: NCT03384563
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine 9 arms
Study: NCT02185014
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection
Study: NCT00442832
Drug: TD-1792
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TD-1792 2 mg/kg/day IV
Study: NCT00442832
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin 1 Gm IV q 12 hrs
Study: NCT03661788
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day treatment interval: first week 40 mg atomoxetine (one pill), second week 80mg atomoxetine (two pills)
Study: NCT01551290
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Form = solution for injection, route = intravenous (IV), Unit = mg/kg, number = 5, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with infliximab through Week 22 will receive infliximab at Weeks 30, 38, 46 and 54, and will receive placebo at Week 32 and 34.
Study: NCT01571908
Drug: Magnesium perfusion
Normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patient receives during 15 minutes a perfusion of 60mg/kg of Magnesium sulphate before induction of anaesthesia.
Study: NCT01571908
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately after anaesthesia induction and loss of consciousness 0,6 mg/kg of rocuronium will be injected
Study: NCT01571908
Drug: Succinylcholine
Normalized name: Succinylcholine
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately after anaesthesia induction at loss of consciousness 1 mg/kg of succinylcholine will be injected
Study: NCT03252093
Drug: Angiotensin-(1-7)
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 200 mcg/kg/day
Study: NCT03252093
Drug: Placebo for Angiotensin-(1-7)
Normalized name: Angiotensin (1-7)
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of Placebo
Study: NCT02120092
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1x Loading dose 600 mg 6x maintenance dose 150 mg
Study: NCT02120092
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1x Loading dose: 180 mg 6x Maintenance dose: 90 mg bid
Study: NCT02120092
Drug: ASA
Normalized name: ASA
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7x 100mg acetylsalicylic acid (clopidogrel arm)~1x 300 mg acetylsalicylic acid (ticagrelor arm)
Study: NCT01550341
Drug: Buprenorphine/naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
Study: NCT03049267
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fifteen patients will be supplied of apremilast for daily oral use; 16 weeks.
Study: NCT00002522
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002522
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01884558
Drug: isavuconazole
Normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01884558
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral
Study: NCT03807297
Drug: Injection dexmedetomidine
Normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: alpha 2 a agonist used for sedation, analgesia
Study: NCT03807297
Drug: Injection, Propofol, 10 Mg
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: non barbiturate type of intravenous anaesthetic drug
Study: NCT00985907
Drug: Doxil, melphalan, bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Doxil®: IV over 30-60 min, Day 1 q28d~Melphalan: IV over 30 min, Day 1 q28d~Velcade®: IV bolus, Day 1, 4, 8, 11 q28d~Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2~Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2
Study: NCT02044601
Drug: Onartuzumab
Normalized name: Onartuzumab
DrugBank: Onartuzumab (DB11746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle.~Phase II: Maximum tolerated dose from Phase I.
Study: NCT02044601
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I and II: 150 mg by mouth every day throughout radiation, except for chemotherapy day.
Study: NCT02044601
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase I and II: 45 mg/m2 by vein once a week throughout radiation for 7 weeks.
Study: NCT02044601
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase I and II: AUC 2 by vein once a week throughout radiation for 7 weeks.
Study: NCT00346502
Drug: 20% betulinic acid ointment
DrugBank: Betulinic Acid (DB12480)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00346502
Drug: BA
Normalized name: Ba
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% Betulinic Acid Ointment
Study: NCT02368912
Drug: ASP1707 single dose of dose levels 1 -7
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, dose escalation
Study: NCT02368912
Drug: ASP1707 multiple dose of dose levels 1-4
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, multiple dose escalation, healthy elderly male
Study: NCT02368912
Drug: ASP1707 multiple dose of dose levels 1-2
Normalized name: 2-hydroxyethyl ether of ethyl cellulose
DrugBank: Hydroxyethyl ethylcellulose (DB14139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, multiple dose escalation, healthy pre-menopausal female
Study: NCT02368912
Drug: ASP1707 parallel multiple dose of dose levels 1-3
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, multiple dose, healthy pre-menopausal female
Study: NCT02725593
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.
Study: NCT02725593
Drug: Dapagliflozin placebo
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
Study: NCT04126720
Drug: Topical corticosteroid and placebo capsules
Normalized name: abiraterone and corticosteroids
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04374591
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation of Sodium Bicarbonate 8.4% via nebulizer
Study: NCT02723006
Drug: TAK-580
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-580 tablets
Study: NCT03691623
Drug: EDP-938 Dose 1
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension for 5 days
Study: NCT03691623
Drug: EDP-938 Dose 2
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension for 5 days
Study: NCT02723006
Drug: TAK-202
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-202 infusion
Study: NCT02723006
Drug: vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: vedolizumab infusion
Study: NCT02723006
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nivolumab infusion
Study: NCT02723006
Drug: ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab infusion
Study: NCT00496483
Drug: LCP Tacro (tacrolimus)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.
Study: NCT00496483
Drug: Prograf
Normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.
Study: NCT00762567
Drug: phenylephrine HCl
Normalized name: Phenylephrine HCl
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule
Study: NCT04449939
Drug: KY1005
Normalized name: Immunoglobulin g4 (235-proline,242-glutamic acid), anti-(human ox40 ligand) (human monoclonal ky1005-2d10 .gamma.4-chain), disulfide with human monoclonal ky1005-2d10 .kappa.-chain, dimer
DrugBank: Amlitelimab (DB18835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A human anti-OX40 ligand monoclonal antibody
Study: NCT00571246
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants are randomized to take Topiramate (250mg/day) 2 times a day
Study: NCT00571246
Drug: lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants are randomized to take Lamotrigine (250 mg/day) 2 times a day
Study: NCT01925911
Drug: IPI-145
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg BID Oral Capsule
Study: NCT01925911
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg midazolam syrup
Study: NCT01451229
Drug: higenamine
Normalized name: Higenamine
DrugBank: Higenamine (DB12779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: infused intravenously with higenamine at the escalating doses from 0.5 ug/kg/min through 1.0 ug/kg/min and 2.0 ug/kg/min to 4.0 ug/kg/min, each dose being given for 3 minutes
Study: NCT00003671
Drug: asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003671
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003671
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003671
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003671
Drug: thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003671
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00504504
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.
Study: NCT00504504
Drug: Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
Study: NCT00504504
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 U/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
Study: NCT03691623
Drug: EDP-938 Dose 3
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension for 5 days
Study: NCT03691623
Drug: EDP-938 Dose 4
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension for 5 days
Study: NCT00504504
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
Study: NCT00504504
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 375 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
Study: NCT00539383
Drug: ANG1005
Normalized name: ANG1005
DrugBank: ANG1005 (DB18167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion once every 21 days
Study: NCT01304212
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The lock is held before starting the operation, viewing with ultrasound and confirmed the femoral nerve with nerve stimulation at an intensity of 0.5 mA and a frequency of 2 Hz Pajunk 50mm needle, patellar flexion. It be administered 30ml of ropivacaine 0.75% (225mg)
Study: NCT01691885
Drug: Fluticasone Furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mcg Once daily
Study: NCT01691885
Drug: Vilanterol
Normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mcg Once daily
Study: NCT03517930
Drug: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)
Normalized name: loratadine / pseudoephedrine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
Study: NCT03517930
Drug: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Normalized name: loratadine / pseudoephedrine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
Study: NCT03817320
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Days 1, 4, 8, and 11. Note: at least 72 hours must have elapsed between doses~Dose Phase 1 - Assigned upon study entry.~Phase 2 - PO formulation at RP2D
Study: NCT03817320
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV push over 1 minute or infusion via minibag as per institutional policy~Days 1, 8, 15 and 22~Dose: ≥ 1 year: 1.5mg/m2/dose (maximum dose 2mg)~≥ 6 months and \< 1 year: 1.2mg/m2/dose~\< 6 months: 1mg/m2/dose
Study: NCT03817320
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days 1-14~Dose: ≥ 1 year: 10mg/m2/day, divided BID (i.e., 5mg/m2/dose, BID)~≥ 6 months and \< 1 year: 8mg/m2/day, divided BID (i.e., 4 mg/m2/dose, BID)~\< 6 months: 7mg/m2/day, divided BID (i.e., 3.5 mg/m2/dose, BID)
Study: NCT03817320
Drug: Asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Days 2, 15~Dose ≥ 1 year: 2,500 International units (IU)/m2/dose~≥ 6 months and \< 1 year: 2,000 IU/m2/dose~\< 6 months: 1,750 IU/m2/dose~Patient with allergic reaction to Pegaspargase can be given Erwinase IM/IV on Mon/Wed/Fri (or every other day per institutional standard) x 6 doses for each dose of Pegaspargase.~Dosing guideline for Erwinase:~* 1 year: 25,000 IU/m2/dose~* 6 months and \< 1 year: 20,000 IU/m2/dose~\< 6 months: 17,500 IU/m2/dose
Study: NCT03817320
Drug: Triple IT (Methotrexate, Hydrocortisone, Cytarabine)
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For patients with CNS 3, on Days 1, 8, 15, 22, and 29
Study: NCT00090142
Drug: Comparator: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
Study: NCT01098955
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg daily for 12 weeks
Study: NCT04185649
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
Study: NCT00037817
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: assigned dose level on day 4 and day 10 of each 34 day cycle
Study: NCT01215110
Drug: Rifafour e-275 mg
Normalized name: vitamin E 50 MG
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03926000
Drug: Pregabalin (PG)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 150 mg one hour before the procedure as premedication.
Study: NCT02816710
Drug: Conbercept
Normalized name: Conbercept
DrugBank: Conbercept (DB12460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.
Study: NCT01882010
Drug: sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lyophilized 250 micrograms/vial~6 micrograms/kg daily subcutaneous injection~56 days